When I was little, my dad had a pet Gila monster.
We lived in Tucson, and very regularly the Gila monster would slither up the back porch and snack on some tasty treats we’d left for him.
It was a completely stupid idea, and potentially illegal. Gila monsters are venomous and shouldn’t be handled.
But there’s something really interesting about their venom.
It has something called exendin-4, which helps the Gila monster regulate its blood sugar.
Scientists discovered this mechanism in the ‘90s. They isolated the chemical and found it works very similarly to something called “glucagon-like-peptide-1.”
You may know that by its more common name: GLP-1.
GLP-1 agonists mimic the peptide, which causes your body to work better with blood sugar. That’s why it was approved for Type 2 diabetes.
Then they found that it’s really effective for helping people lose weight. Liraglutide was approved in 2014, and then semaglutide was approved in 2021.
Ely Lilly (LLY) and Novo Nordisk (NVO) were the big winners:
They saw 300-400% gains after that catalyst.
Now, I’m a self-admitted nerd. I was biohacking way before it was cool or trendy.
I’ve known about peptides for a long time. And I can tell you, if you’re only looking at Ozempic and Wegovy, you’re already behind the 8-ball.
Drugs like BPC157 or MK-677 are making their way into the mainstream, and they’ve been around a long, long time.
But I’ve just stumbled on a little pharma company that’s working on drugs that could be the next wave of Wegovies and Ozempics.
I explain more in the video above…
Take a look, and then click here to learn more about the early warning signal that tipped me off to this opportunity – plus three others I’m monitoring right now.
